Rottweiler tested, Novo and Sofinnova back $33M round for Rgenix

View article

30-02 48th Ave, Ste 350
Long Island City, NY 11101
(646) 389-9103
info@inspirna.com

Linked In
Twitter

Inspirna, Inc. is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need.

Privacy Policy
Terms of Use
Cookie Notice